Much ado about nothing? Recent FDA alerts and NovoNordisk lawsuits
Due to the blockbuster weight loss drugs Ozempic, Wegovy and Mounjaro going on the FDA Shortage List, compounding pharmacies are legally allowed to make duplicates of these name brand drugs without risk of patent infringement. And even though NovoNordisk, the maker of Ozempic and Wegovy, admits they can’t keep up with demand, they’re trying everything […]
Shame on you Mississippi and West Virginia
Why would Mississippi and West Virginia, states that are ranked #1 and #4 in poverty, #5 and #1 in adult obesity, and #2 and #4 in adolescent obesity, respectively, eliminate access to the most affordable version of the safe and effective weight loss drugs Ozempic and Wegovy? Background on Ozempic and Wegovy Not since […]
Consumers’ misguided focus on the risks surrounding Ozempic and Wegovy
Consumers reluctant to try new weight loss drugs seem to focus more on the least likely risks such as pancreatitis and a rare type of thyroid cancer rather than focusing on the more common side effects like burping, nausea, vomiting, constipation and diarrhea. Instead of focusing on the risks associated with taking the medication, patients […]
Weight Management Webinar Series for Providers
1. Basics of a Weight Mngmt Program – Recording below We’re kicking off this series of 20-minute webinars on weight management programs by going over the basics. Learn how Dr. Jonathan Kaplan created and automated a program that allowed his practice to scale to over 300 patients, producing monthly recurring revenue of $140,000+. He’ll review: Needed […]
Automating your weight management (or any recurring subscription) program
Recently, our office posted a video on TikTok weighing in on whether a celebrity lost weight by diet, exercise and/or the use of the groundbreaking weight loss medication, semaglutide, the active ingredient in Ozempic (approved for type 2 diabetes in 2017) and Wegovy (approved for obesity in 2021) . It was a topic that our […]
Questions about Ozempic and Wegovy? Join our Webinar Q&A!
Join us for an exciting webinar on the most talked about medication since Viagra! Ozempic and Wegovy are changing the discussion around obesity. Dr. Jonathan Kaplan will provide an overview of these medications, answer your questions and discuss how you can get these medications from doctors across the country. Click here to register for the webinar. In the […]
Overview of the Texas Medical Association Lawsuits over the No Surprises Act
Since implementation of the No Surprises Act (NSA) on January 1st, 2022, there have been four lawsuits brought on by the Texas Medical Association (TMA). Interesting that the TMA is more vocal and active legally and supportive of physicians in America than the American Medical Association (AMA). Not sure why anyone would pay dues to […]
Is a post-pandemic recession headed our way?
As I wrote in these pages in July of 20201, the aesthetic business would flourish during the pandemic. Unfortunately, whatever goes up, must come down. We’re experiencing the highest inflation in the last 40 years due a combination of pandemic-era Federal financial stimuli, increased demand for goods and services and supply chain issues. To combat inflation, […]
Automating Weight Management Programs for Better Customer Service
Recently, Dr. Jonathan Kaplan posted a video on TikTok weighing in on whether a celebrity lost weight by diet, exercise and/or the use of the groundbreaking weight loss medication, semaglutide, the active ingredient in Ozempic (approved for type 2 diabetes in 2017) and Wegovy (approved for obesity in 2021) . It was a topic that […]
Convening Provider rule delayed
FAQS ABOUT CONSOLIDATED APPROPRIATIONS ACT, 2021 IMPLEMENTATION – GOOD FAITH ESTIMATES (GFES) FOR UNINSURED (OR SELF-PAY) INDIVIDUALS – PART 3 December 2, 2022 Set out below are Frequently Asked Questions (FAQs) regarding implementation of Section 112 of Title I (the No Surprises Act (NSA)) of Division BB of the Consolidated Appropriations Act, 2021, and implementing […]